AAX Biotech
AAX Biotech is a Swedish biotech spin-out from Karolinska Institutet that licenses Seqitope® (high-throughput epitope mapping) and Opti-mAb® (scFv stabilization) platforms to pharmaceutical and biotech companies developing antibody therapeutics.
- Company typePrivate
- Founded2022
- HeadquartersStockholm, Sweden
- Headcount11–50
- GTM typeB2B
- OfferingServices
What AAX Biotech does
AAX Biotech AB is a privately held Swedish biotech company spun out of Karolinska Institutet in 2022 (with research roots from 2020) and headquartered in Solna, Sweden. The company develops and commercializes two proprietary antibody engineering platforms: Seqitope®, a high-resolution, high-throughput epitope mapping technology based on massive parallel mutagenic scanning combined with next-generation sequencing (NGS), capable of characterizing up to 100 monoclonal antibody candidates in parallel; and Opti-mAb®, a molecular stabilization strategy for single-chain variable fragment (scFv) antibodies that improves expression yields and reduces aggregation for use in bispecific antibodies and CAR-T cell therapies. Both platforms are registered trademarks described as patentable and unique in their respective niches, particularly Opti-mAb which addresses a well-known instability problem in scFv formats with no widely applicable commercial alternative.
The company's business model combines fee-for-service research collaborations, technology licensing, and channel partnerships. Pricing is project-based and quote-driven, with no public rate cards; contracts tend toward multi-year engagements. Its customer base spans large pharmaceutical companies (Daiichi Sankyo, BioArctic), clinical-stage and early-stage biotechs (Vascurie, ToxoTech, Oblique Therapeutics), and academic groups (Karolinska Institutet Tran Research Group), with end applications in oncology, neurology, pain, and cardiovascular disease. Distribution occurs through direct enterprise sales led by the CEO and CBO, conference-based business development (BIO, PEGS, Antibody Engineering & Therapeutics), a Verified Supplier listing on Scientist.com, and a reseller agreement with evitria AG (part of Atlas Antibodies/Patricia Industries) for Opti-mAb research licenses.
The company operates with a small team of fewer than 10 employees. It has raised a 7 MSEK (~$682K) funding round in October 2024 led by Life Science Invest (LSI Epsilon), alongside existing investors Karolinska Institutet Holding, Northislet, Phase2Phase Biopharma Ventures, and HJKK Didrikson. A subsequent investment from Trio Impact Invest AB was announced in February 2026. Revenue figures are not publicly disclosed.
AAX Biotech firmographics
Firmographics- Name
- AAX Biotech
- Legal name
- AAX Biotech AB
- Website
- https://aaxbiotech.com
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- AAX Biotech is a Swedish biotech spin-out from Karolinska Institutet that licenses Seqitope® (high-throughput epitope mapping) and Opti-mAb® (scFv stabilization) platforms to pharmaceutical and biotech companies developing antibody therapeutics.
- Ownership category
- akta.pro rank
AAX Biotech industry classification
Industry- Product category
- Antibody Engineering Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)
- akta.pro secondary industries
- Bispecific & Multispecific Antibodies (HLAAAAAF), Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds) (HLAAAAAJ)
Keywords
Where AAX Biotech is headquartered
LocationHeadquarters
- HQ city
- Stockholm
- HQ country
- Sweden
- HQ region
- Europe
Offices1 record
Markets served
AAX Biotech business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Technology licensing and service contracts: AAX Biotech generates revenue by licensing its proprietary Seqitope® and Opti-mAb® technologies to pharma and biotech companies, and by providing fee-for-service epitope mapping and antibody characterization projects. They execute collaborative research agreements with pharmaceutical partners (e.g., Daiichi Sankyo, Vascurie, ToxoTech, Oblique Therapeutics, BioArctic). Revenue is project-based and recurring as partnerships expand. The company also offers Opti-mAb® under research licenses through partners like evitria AG.
- Fee-for-service research collaborations: AAX Biotech conducts paid research collaborations where partners pay for characterization services using the Seqitope® platform and robotic automation infrastructure. Projects include high-throughput antibody characterization (up to 100 antibodies in parallel). The company also serves as a Verified Supplier on Scientist.com, enabling direct service contracting with pharma and biotech buyers.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Project-based pricing for pharma and biotech companies |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels6 records
AAX Biotech product offering
Product offeringCore offering
AAX Biotech develops and licenses two proprietary antibody technology platforms — Seqitope® for high-resolution, high-throughput epitope mapping (up to 100 monoclonal antibodies analyzed in parallel with single amino acid resolution) and Opti-mAb® for stabilizing scFv antibodies used in bispecific antibodies and CAR-T therapies. The company delivers these platforms through technology licensing arrangements and fee-for-service antibody characterization research collaborations with pharmaceutical, biotech, and academic partners.
Product overview
AAX Biotech operates as a dual-technology platform company offering two proprietary technology platforms for antibody therapeutics development. The core portfolio consists of Seqitope®, a high-resolution and high-throughput epitope mapping technology that processes up to 100 monoclonal antibodies in parallel, and Opti-mAb®, a novel scFv molecular stabilization technology that improves expression yields and reduces aggregation for next-generation antibody formats. Both technologies aim to accelerate drug development and improve therapeutic performance of antibody-based medicines including bispecific antibodies and CAR-T cell therapies.
Differentiator
Problem solved
Functional benefit
Products and services
- Seqitope® Seqitope® is a high-resolution, high-throughput antibody epitope mapping platform based on massive parallel mutagenic scanning combined with next-generation sequencing. It processes up to 100 monoclonal antibody candidates in parallel at single amino acid resolution, accelerating antibody discovery, de-risking lead candidate selection, and supporting antibody affinity maturation. The platform is licensed to and used in fee-for-service research collaborations with pharmaceutical, biotech, and academic customers developing antibody therapeutics including bispecific antibodies, monoclonal antibodies, and CAR-T therapies.
- Opti-mAb® Opti-mAb® is a novel scFv molecular stabilization format that dramatically improves expression levels and reduces aggregation tendencies of single-chain variable fragment antibodies. It addresses the inherent instability problem of scFvs used in CAR-T cell therapies, bispecific antibodies, and other next-generation antibody therapeutics, improving production yields, reducing development costs, and enhancing pharmacological properties. The technology is licensed to pharmaceutical and biotech partners (including through channel partner evitria AG) and evaluated with collaborators such as Daiichi Sankyo.
Quantifiable outcome
- Up to 100 antibodies characterized in parallel using Seqitope® platform with robotic automation infrastructure
- +3 more outcomes
Companies that use AAX Biotech
Customer profileNamed customers7 records
Segments2 records
Ideal customer profiles2 records
AAX Biotech technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability6 records
Feature2 records
AAX Biotech partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered core and minor.
- Karolinska Institutet (Tran Research Group)coreCollaboration with Dr. Thuy Tran's research group at the Department of Oncology-Pathology, Karolinska Institutet. AAX Biotech applies Seqitope® to characterize novel anti-TROP2 antibodies developed by the Tran group and elucidate molecular features differentiating them from established TROP2 binders. TROP2 is a clinically validated cancer target with complex structure making characterization challenging.
- evitria AGcorePartnership with evitria AG, an expert provider of antibody engineering and expression services based in Zurich, Switzerland. evitria offers access to Opti-mAb® technology in early antibody development workflows, providing research licenses and incorporating the technology into multispecific antibody formats. evitria is part of the Atlas Antibodies group, a wholly-owned subsidiary of Patricia Industries.
- Nordic Mentor Network for Entrepreneurship (NOME)minorAAX Biotech was accepted into NOME, a Nordic mentor network providing tailored support from world-class mentors including Christine Richter, Magnus Björsne, Göran Forsberg, and Thorsten Thormann to strengthen commercial strategy and accelerate leadership in antibody-based medicine technologies.
- VascuriecoreCollaboration with neuro-oncology therapeutics developer Vascurie to advance high-throughput antibody characterization. AAX Biotech applies Seqitope® platform and robotic automation to characterize Vascurie's antibody candidates targeting CD93, a novel drug target. AAX Biotech can characterize up to 100 antibodies in parallel, providing rapid insights for Vascurie's neuro-oncology programs including lead candidate VDL-309. IND/CTA submission targeted for 2027 by Vascurie.
- ToxoTechcoreStrategic collaboration to develop next-generation biotherapeutics for neurological disorders. The partnership combines AAX's Seqitope® platform with ToxoTech's expertise in biologic drug design to create novel biotherapeutic candidates with improved potency and precision. Seqitope® is applied to optimize receptor recognition and generate novel variants for neuromuscular and neurological indications.
- Daiichi SankyocoreCollaboration with global pharmaceutical leader Daiichi Sankyo (one of the global leaders in antibody-drug conjugates) to evaluate Opti-mAb® technology for next-generation antibody therapeutics. Conducted through Daiichi Sankyo's Munich research institute, the collaboration aims to explore broader applications of the platform to address medical needs. Represents significant validation of AAX Biotech's innovative approach.
- Confidential partner (clinical-stage cardiovascular program)coreNew collaboration focused on developing antibody-based therapies for acute and critical care of cardiovascular disease. AAX Biotech applies Seqitope® technology to conduct advanced epitope mapping of a humanized monoclonal antibody in clinical development, supporting regulatory submissions and optimizing clinical advancement.
- BioArcticcoreBioArctic AB, a Swedish biopharma company focused on neurodegenerative diseases, decided to utilize AAX Biotech's proprietary Seqitope™ epitope mapping technology in a research project. This collaboration represents a significant milestone highlighting AAX Biotech's role in advancing neurodegenerative disease research.
- Oblique TherapeuticscoreStrategic collaboration where AAX Biotech applies Seqitope™ technology to characterize antibody candidates of Oblique Therapeutics' pain program targeting TRPV1, providing invaluable insights for development. The collaboration represents the start of a broader and lasting collaboration on future drug candidates. Oblique Therapeutics noted that Seqitope® provided previously unattainable level of insight into drug candidate-target interactions.
Scale indicators2 records
Recent moves6 records
Expansion highlights6 records
AAX Biotech competitors and assessment
Company assessmentDirect peers
- Oblique Therapeutics: Swedish biotech developing antibody therapeutics (TRPV1 pain program). AAX Biotech is an existing partner using Seqitope for their antibody candidates; both are Swedish antibody-focused biotechs of comparable scale.
- BioArctic: Swedish biopharma focused on neurodegenerative diseases that has licensed Seqitope for antibody characterization. Comparable Swedish antibody/biologics peer serving similar therapeutic areas (neuro, oncology).
- Salipro Biotech: Swedish biotech platform company developing technology for membrane protein-based drug discovery (where CBO Maria Lisa Knudsen previously served as BD Director). Comparable Swedish biotech platform of similar scale.
- evitria AG: Zurich-based antibody engineering and expression services provider (Atlas Antibodies/Patricia Industries subsidiary) that resells Opti-mAb research licenses. Directly comparable service provider in antibody engineering workflows.
- AbCellera Biologics: Vancouver-based antibody discovery platform combining high-throughput screening, microfluidics, and AI to identify antibody candidates. Most directly comparable platform peer offering antibody discovery technology to pharma partners.
- Adimab: US-based antibody discovery and engineering platform offering yeast-based high-throughput antibody screening and optimization to pharma partners. Closely comparable business model and customer base to AAX Biotech.
Broad incumbents
- GenScript: Global biotech services company providing antibody discovery, synthesis, and characterization services at scale. Larger, broader player with overlapping capabilities in antibody R&D services that pharma buyers may compare AAX against.
- Bio-Techne: Large life-sciences tools and reagents company with antibody-related products and services. Broader incumbent that competes for similar antibody-tooling budgets within pharma/biotech customers.
- Charles River Laboratories: Global CRO offering extensive antibody discovery, characterization, and biologics manufacturing services. Larger incumbent serving the same enterprise pharma/biotech buyers with broader service portfolios.
Emerging players
- SystImmune: US-based clinical-stage biotech developing bispecific and ADC antibody therapeutics. Relevant emerging peer as a potential customer for Opti-mAb scFv stabilization in bispecific workflows.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
AAX Biotech social profiles
Digital presenceAAX Biotech financial estimates
Financial estimateRevenue estimate
Valuation estimate
AAX Biotech leadership team
Management profileNumber of profiles
Profiles12 records
AAX Biotech funding detail
Funding detailFunding overview
Funding rounds2 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
AAX Biotech M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about AAX Biotech
What does AAX Biotech do?
AAX Biotech develops and licenses two proprietary antibody technology platforms — Seqitope® for high-resolution, high-throughput epitope mapping (up to 100 monoclonal antibodies analyzed in parallel with single amino acid resolution) and Opti-mAb® for stabilizing scFv antibodies used in bispecific antibodies and CAR-T therapies. The company delivers these platforms through technology licensing arrangements and fee-for-service antibody characterization research collaborations with pharmaceutical, biotech, and academic partners.
Is AAX Biotech a public or private company?
AAX Biotech is a private company. It is classified as venture growth investor backed and is currently operating.
When was AAX Biotech founded?
AAX Biotech was founded in 2022. It employs 11 to 50 people.
Where is AAX Biotech based?
AAX Biotech is headquartered in Stockholm, Sweden, in the Europe region.
How does AAX Biotech make money?
Two revenue lines are on record. Technology licensing and service contracts are the primary driver. The others are fee-for-service research collaborations.
Who are AAX Biotech's main competitors?
Direct peers on record are Oblique Therapeutics, BioArctic, Salipro Biotech, evitria AG, AbCellera Biologics and Adimab. Broad incumbents are GenScript, Bio-Techne and Charles River Laboratories. SystImmune is listed as an emerging player.
Does AAX Biotech have an API?
No public API is recorded for AAX Biotech.
What industry is AAX Biotech in?
AAX Biotech's product category is Antibody Engineering Services. Its primary akta.pro industry code is HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering), with a secondary code of HLAAAAAF, Bispecific & Multispecific Antibodies. Its NAICS code is 541714 and its SIC code is 2836.